title: Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index.
abstract: OBJECTIVE
  Hyperfractionated and accelerated radiotherapy without a split was performed to improve the local control probability of early glottic carcinomas. We analyzed the results of this regimen by using the Ki-67 index.
  
  
  METHODS
  Over a 12-year period, 85 T1N0M0 glottic cancers and 50 T2N0M0 glottic cancers were treated with conventional fractionation (CF) from 1984 to 1989 and with accelerated fractionation (AF) since 1990. The CF program consisted of five daily fractions of 2 Gy per week, for a total of 64 Gy. The AF program consisted of 1.72 Gy per fraction, two fractions per day, 5 days a week, for a total of 55 or 58 Gy. The specimens, taken before radiotherapy, were immunohistochemically stained with anti-Ki-67 antibody.
  
  
  RESULTS
  The 5-year local control probability for T1 tumors was 79.6 +/- 6.9% with CF treatment, whereas with AF it was 86.9 +/- 5.6%. For T2 tumors it was 62.7 +/- 12.2% with CF, whereas it was 74.7 +/- 7.8% with AF. The difference between CF and AF did not reach the point of statistical significance. However, when T1 tumors had a Ki-67 index lower than 50%, the local control rate achieved with AF was significantly better than that with CF (p = 0.018). When the tumors had a Ki-67 index that was 50% or more, there was no difference in the local control rate between CF and AF, whether they were T1 or T2. The peak mucosal reactions at the larynx and/or hypopharynx were much more severe and appeared at smaller doses and earlier in AF than in CF. The patients with AF showed no severe late complications.
  
  
  CONCLUSIONS
  AF could not obtain statistically significant improvement in local control probability of T1 or T2 glottic carcinomas.
authors.affiliation: Department of Radiology, Sapporo Medical University, School of Medicine, Sapporo, Japan. sakatako@sapmed.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Sakata
authors.forename: A
authors.initials: A
authors.lastname: Oouchi
authors.forename: H
authors.initials: H
authors.lastname: Nagakura
authors.forename: H
authors.initials: H
authors.lastname: Akiba
authors.forename: M
authors.initials: M
authors.lastname: Tamakawa
authors.forename: K
authors.initials: K
authors.lastname: Koito
authors.forename: M
authors.initials: M
authors.lastname: Hareyama
authors.forename: K
authors.initials: K
authors.lastname: Asakura
authors.forename: M
authors.initials: M
authors.lastname: Satoh
authors.forename: S
authors.initials: S
authors.lastname: Ohtani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000473:pathology / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D005260:Female; D005931:Glottis / Q000528:radiation effects; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D007822:Laryngeal Neoplasms / Q000737:chemistry / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000528:radiation effects; D009367:Neoplasm Staging; D016879:Salvage Therapy; D013280:Stomatitis / Q000209:etiology; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen